How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

Overview

Journal Front Genet

Date 2020 Dec 28

PMID 33363564

Citations 15

Authors

Beatriz Carvalho Henriques

Esther H Yang

Diego Lapetina

Michael S Carr

Vasyl Yavorskyy

Joshua Hague

Katherine J Aitchison

Affiliations

Soon will be listed here.

Abstract

Many genetic variants in drug metabolizing enzymes and transporters have been shown to be relevant for treating psychiatric disorders. Associations are strong enough to feature on drug labels and for prescribing guidelines based on such data. A range of commercial tests are available; however, there is variability in included genetic variants, methodology, and interpretation. We herein provide relevant background for understanding clinical associations with specific variants, other factors that are relevant to consider when interpreting such data (such as age, gender, drug-drug interactions), and summarize the data relevant to clinical utility of pharmacogenetic testing in psychiatry and the available prescribing guidelines. We also highlight areas for future research focus in this field.

Citing Articles

The role of polymorphic cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia (B-CLL) incidence and outcome among Egyptian patients.

Al-Adl M, Youssef M, El-Sebaie A, Refaat S, El-Said A Oncol Res. 2024; 32(4):785-797.

PMID: 38560574 PMC: 10972729. DOI: 10.32604/or.2024.047021.

Deb S, Hopefl R, Reeves A, Cvetkovic D Medicines (Basel). 2024; 11(3).

PMID: 38535119 PMC: 10972161. DOI: 10.3390/medicines11030006.

The therapeutic landscape for COVID-19 and post-COVID-19 medications from genetic profiling of the Vietnamese population and a predictive model of drug-drug interaction for comorbid COVID-19 patients.

Nguyen T, Vu G, Duong V, Pham T, Nguyen N, Tran T Heliyon. 2024; 10(6):e27043.

PMID: 38509882 PMC: 10950508. DOI: 10.1016/j.heliyon.2024.e27043.

Haplotype phasing of CYP2D6: an allelic ratio method using Agena MassARRAY data.

Thamilselvan M, Mather C, Wang Y, Foo J, Aitchison K Transl Psychiatry. 2024; 14(1):91.

PMID: 38346976 PMC: 10861455. DOI: 10.1038/s41398-024-02809-y.

Therapeutic Drug Monitoring and Pharmacogenetic Testing as Guides to Psychotropic Drug Dose Adjustment: An Observational Study.

Cuvelier E, Khazri H, Lecluse C, Hennart B, Amad A, Roche J Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256855 PMC: 10818858. DOI: 10.3390/ph17010021.

References

Bauer B, Hartz A, Fricker G, Miller D . Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol. 2004; 66(3):413-9. DOI: 10.1124/mol.66.3.. View

Pinto N, Dolan M . Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011; 12(5):487-97. PMC: 3110519. DOI: 10.2174/138920011795495321. View

Aitchison K, Bienroth M, Cookson J, Gray R, Haddad P, Moore B . A UK consensus on the administration of aripiprazole for the treatment of mania. J Psychopharmacol. 2008; 23(3):231-40. DOI: 10.1177/0269881108098820. View

Ehlert F, Delen F, Yun S, Liem H . The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990; 253(1):13-9. View

Tateishi T, Watanabe M, Kumai T, Tanaka M, Moriya H, Yamaguchi S . CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2001; 67(24):2913-20. DOI: 10.1016/s0024-3205(00)00874-2. View

Chatzistefanidis D, Georgiou I, Kyritsis A, Markoula S . Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid. Pharmacogenomics. 2012; 13(9):1055-71. DOI: 10.2217/pgs.12.78. View

Krueger S, Williams D . Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005; 106(3):357-87. PMC: 1828602. DOI: 10.1016/j.pharmthera.2005.01.001. View

Hansen L, Larsen N, Gulmann N . Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berl). 1982; 78(2):112-5. DOI: 10.1007/BF00432245. View

Cartmell M, Schulz H, OReilly D, Yang B, Kielstein V, Dunlop S . Cytochrome P450 2E1 high activity polymorphism in alcohol abuse and end-organ disease. World J Gastroenterol. 2006; 11(41):6445-9. PMC: 4355784. DOI: 10.3748/wjg.v11.i41.6445. View

10.

Nuntamool N, Ngamsamut N, Vanwong N, Puangpetch A, Chamnanphon M, Hongkaew Y . Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents. Basic Clin Pharmacol Toxicol. 2017; 121(4):316-324. DOI: 10.1111/bcpt.12803. View

11.

Christensen M, Tybring G, Mihara K, Carrillo J, Ramos S, Andersson K . Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002; 71(3):141-52. DOI: 10.1067/mcp.2002.121788. View

12.

Heit C, Dong H, Chen Y, Thompson D, Deitrich R, Vasiliou V . The role of CYP2E1 in alcohol metabolism and sensitivity in the central nervous system. Subcell Biochem. 2013; 67:235-47. PMC: 4314297. DOI: 10.1007/978-94-007-5881-0_8. View

13.

Puranik Y, Birnbaum A, Marino S, Ahmed G, Cloyd J, Remmel R . Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2012; 14(1):35-45. PMC: 3570048. DOI: 10.2217/pgs.12.180. View

14.

Mailman R, Murthy V . Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr Pharm Des. 2009; 16(5):488-501. PMC: 2958217. DOI: 10.2174/138161210790361461. View

15.

Tang M, Pinsky E . Mood and affect disorders. Pediatr Rev. 2015; 36(2):52-60. DOI: 10.1542/pir.36-2-52. View

16.

Fan W, Shiao M, Hui R, Su S, Wang C, Chang Y . HLA Association with Drug-Induced Adverse Reactions. J Immunol Res. 2018; 2017:3186328. PMC: 5733150. DOI: 10.1155/2017/3186328. View

17.

Malhi G, Mann J . Depression. Lancet. 2018; 392(10161):2299-2312. DOI: 10.1016/S0140-6736(18)31948-2. View

18.

Molden E, Waade R, Hoff M, Haslemo T . Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. Basic Clin Pharmacol Toxicol. 2016; 119(5):470-475. DOI: 10.1111/bcpt.12614. View

19.

Bertilsson L, Dahl M, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I . Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet. 1993; 341(8836):63. DOI: 10.1016/0140-6736(93)92546-6. View

20.

Sim S . CYP1A2*1E [corrected] contains the -163C>A substitution and is highly inducible. Pharmacogenet Genomics. 2013; 23(2):104-5. DOI: 10.1097/FPC.0b013e32835ccc76. View